Core views

On the evening of August 28, the company released its 2023 semi-annual report. Achieving operating income, net profit attributable to parents, and net profit after deduction were 6.791 billion yuan, 1,606 billion yuan, and 1,541 billion yuan respectively, with year-on-year increases of 21.99%, 53.16%, and 46.67%, respectively; overall performance was in line with previous expectations. Q2 The decline in profit in a single quarter was mainly due to: ① Highly profitable cold-resistant categories saw a decline in sales revenue from a high base for the same period last year; ② cost increases due to increases in raw material prices; ③ sales expenses increased compared to the same period last year. As the company's product development bureau continues to advance and continues to consolidate its leading position in innovative traditional Chinese medicine, it is expected to achieve long-term high-quality development.

occurrences

The company released its 2023 semi-annual report

On the evening of August 28, the company released its semi-annual report for 2023. Achieving operating income, net profit attributable to parents, and net profit after deduction were 6.791 billion yuan, 1,606 billion yuan, and 1,541 billion yuan respectively, with year-on-year increases of 21.99%, 53.16%, and 46.67%, respectively; overall performance was in line with previous expectations.

Brief review

Quarterly results from a high base are under pressure, and overall performance is in line with expectations